Substance use treatment: the kickback law that doesn't care about your payor mix

Everything on the healthcare structuring core applies to a substance use treatment provider: corporate practice of medicine where relevant, the friendly-PC and MSO model, federal fraud and abuse law, and licensing and CHOW-style continuity concerns. What’s specific to this niche is a federal statute written specifically because of scandals in this industry, and it reaches further than the general fraud and abuse rules the core page describes.

The statute that doesn’t stop at Medicare and Medicaid

The federal Anti-Kickback Statute and Stark Law, covered on the core page, generally apply to care paid for by federal healthcare programs, Medicare and Medicaid specifically. A separate federal law, enacted directly in response to patient-brokering scandals in addiction treatment and sober living arrangements, reaches substantially further: it applies to referral and kickback arrangements regardless of whether the patient’s care is paid for by a federal program, private insurance, or cash. This is the single most important structural fact in this niche, and it’s the one new operators most commonly miss. A treatment provider that serves only privately insured or self-pay patients, with zero Medicare or Medicaid billing, is not exempt from federal kickback scrutiny the way that same fact pattern would exempt an ordinary medical practice from the Anti-Kickback Statute and Stark Law specifically. Stopping the compliance analysis at “we don’t take Medicaid, so kickback law doesn’t apply” is exactly the mistake this statute exists to catch.

The structuring consequence this actually forces

Because this reach extends to commercial and private-pay arrangements, every referral relationship this niche commonly relies on, marketing affiliates, call centers, sober living homes sending clients into treatment, needs to be structured the same way regardless of how those particular patients are paying. The safe structure compensates for actual services rendered, at a fixed or fair-market-value rate, documented in a real agreement, never as a per-referral or per-admission payment tied to the volume or value of patients sent. A marketing agreement that pays a flat fee for genuine advertising services is a different animal, legally, from one that pays a bonus scaled to how many patients actually enrolled, even if both arrangements are with the exact same marketing company and even if every patient involved is paying entirely out of pocket. The entity structure for any marketing, patient-acquisition, or referral-facilitation function in this niche needs its compensation model reviewed against this standard specifically, not against the narrower federal-program-only test that governs most of the rest of healthcare.

Records confidentiality runs on a stricter track too

Substance use treatment records carry their own federal confidentiality framework, layered on top of ordinary HIPAA, with tighter default restrictions on sharing patient information, including with other treatment providers, absent the patient’s specific consent. A structure or a referral relationship built assuming standard HIPAA-level information sharing is sufficient can find itself non-compliant with this stricter, substance-use-specific standard even where the underlying HIPAA analysis was done correctly.

Where this hands off

The entity mechanics behind a treatment provider’s structure live in State Lines and The Blueprint. This page’s job is narrower: recognizing that this niche’s payor-blind kickback exposure means every marketing and referral relationship needs review under a broader standard than the rest of healthcare uses, regardless of how the patients in question happen to be paying.